These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2043 related items for PubMed ID: 16303216

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D, Kakazo M, Saleu G, Taime J, Javati A, Namuigi P, Alpers MP, Wegmüller B, Zellmeyer M, Fürer E, Que JU, Herzog C.
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA, Meschievitz CK, Ballanco GA, Daum RS.
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [Abstract] [Full Text] [Related]

  • 5. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C, Thisyakorn U, Chotpitayasunondh T, Fürer E, Que JU, Hasler T, Cryz SJ.
    Bull World Health Organ; 2000 Apr; 78(3):364-71. PubMed ID: 10812736
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
    Huebner RE, Nicol M, Mothupi R, Käyhty H, Mbelle N, Khomo E, Klugman KP.
    Vaccine; 2004 Dec 21; 23(6):802-6. PubMed ID: 15542205
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H, McIntyre P, Roberton D, Dinan L, Hardt K.
    Int J Infect Dis; 2010 Jan 21; 14(1):e41-9. PubMed ID: 19467896
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA, King J, Law B, Mills E, Willems P.
    Clin Infect Dis; 1999 May 21; 28(5):995-1001. PubMed ID: 10452624
    [Abstract] [Full Text] [Related]

  • 14. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A, Hutagalung Y, Watanaveeradej V, Bock HL, Steinhoffmd M.
    J Med Assoc Thai; 2007 Jul 21; 90(7):1330-6. PubMed ID: 17710973
    [Abstract] [Full Text] [Related]

  • 15. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
    Pace D, Snape M, Westcar S, Hamaluba M, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ.
    Pediatr Infect Dis J; 2007 Nov 21; 26(11):1057-9. PubMed ID: 17984816
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.
    Vaccine; 2009 Apr 28; 27(19):2540-7. PubMed ID: 19124057
    [Abstract] [Full Text] [Related]

  • 17. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Nov 28; 11(6):488-95. PubMed ID: 17349809
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D, HibMenCY-TT 005 Study Group.
    Pediatr Infect Dis J; 2010 Jan 28; 29(1):48-52. PubMed ID: 20035207
    [Abstract] [Full Text] [Related]

  • 19. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H.
    Lancet; 2010 Jan 28; 348(9043):1688-92. PubMed ID: 8973430
    [Abstract] [Full Text] [Related]

  • 20. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ, Knuf M, Ortiz E, Sänger R, Uwamwezi MC, Kaufhold A.
    J Pediatr; 2000 Sep 28; 137(3):304-12. PubMed ID: 10969252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 103.